Peptides for Recovery: BPC-157, TB-500 & What the Research Shows

People researching peptides for recovery often encounter BPC-157 and TB-500, especially in conversations about tendon, ligament, muscle, injury and tissue recovery.

Interest and real-world use have grown faster than the clinical research. This page separates human evidence, preclinical research, real-world experience and regulatory status so readers can understand both why these peptides are popular and what the evidence currently supports.

Evidence at a Glance

Human Evidence: Limited

There is very little controlled human evidence supporting BPC-157 or TB-500 for musculoskeletal recovery.

Preclinical Evidence: More substantial

BPC-157 has been investigated across animal models involving tendon, ligament, muscle and bone injuries. Translation to human recovery remains uncertain.

Real-World Experience: Commonly discussed

BPC-157 and TB-500 are widely discussed in fitness, athletic and recovery communities. These experiences help explain their popularity but are not equivalent to controlled clinical evidence.

Regulatory Status: Important

Neither BPC-157 nor TB-500 is FDA-approved as a treatment for musculoskeletal recovery.

Primary Compounds

BPC-157

BPC-157 is one of the most frequently discussed experimental peptides for tendon, ligament, muscle and injury recovery.

Animal research has investigated BPC-157 across multiple musculoskeletal injury models, including tendon, ligament, muscle and bone. Recent systematic review evidence shows that this literature remains overwhelmingly preclinical, with very limited human evidence.

Handbook interpretation: Promising preclinical recovery research. Very limited human evidence. Review the BPC-157 compound profile.

TB-500

TB-500 is frequently associated with tissue repair, wound healing and athletic recovery discussions.

TB-500 should not simply be presented as another name for full-length thymosin beta-4. It is a related peptide fragment, and evidence involving thymosin beta-4 must not automatically be attributed to TB-500.

Direct human evidence demonstrating improved musculoskeletal recovery from TB-500 remains inadequate.

Handbook interpretation: Biologically interesting and widely discussed for recovery, but direct human recovery evidence is weak. Review the TB-500 compound profile.

BPC-157 vs. TB-500

BPC-157

  • Common recovery interest: Tendon, ligament, muscle and injury recovery
  • Research context: Substantial musculoskeletal preclinical literature
  • Human evidence: Very limited
  • Community discussion: Frequent
  • FDA-approved for recovery: No

TB-500

  • Common recovery interest: Tissue repair, wound healing and recovery
  • Research context: Direct TB-500 evidence is limited; related thymosin beta-4 research is broader
  • Human evidence: Very limited
  • Community discussion: Frequent
  • FDA-approved for recovery: No

What Is the Wolverine Stack?

"Wolverine Stack" is a community term commonly used for the combination of BPC-157 and TB-500.

It has become associated with recovery and tissue-healing discussions in peptide communities.

Evidence involving BPC-157 or TB-500 individually does not establish that combining them produces better recovery outcomes.

Recovery Context

Tendon & Ligament

BPC-157 has produced encouraging findings in animal tendon and ligament injury models. Human evidence remains extremely limited.

Muscle

Preclinical BPC-157 studies have also investigated muscle injury and recovery, but clinical effectiveness has not been established.

Tissue Repair

TB-500 is frequently discussed in relation to tissue and wound repair, but direct evidence supporting musculoskeletal recovery in humans remains very limited.

What People Report Using Them For

Real-world experience is one reason BPC-157 and TB-500 have become so prominent in recovery discussions.

  • Tendon and ligament recovery
  • Nagging sports injuries
  • Muscle recovery
  • Joint-related recovery
  • Tissue repair
  • Returning to training after injury

These reports are useful for understanding what people are trying to achieve and why these peptides have become popular. They do not establish that a compound caused an improvement. Injury recovery, rehabilitation, training changes and other factors can influence individual outcomes.

Safety & Regulatory Status

Neither BPC-157 nor TB-500 is an FDA-approved treatment for musculoskeletal recovery.

FDA has recently evaluated BPC-157-related and TB-500-related bulk substances in the compounding context. Those regulatory reviews should not be presented as FDA validation of popular athletic-recovery uses.

For competitive athletes, antidoping rules are also relevant. TB-500 and thymosin-beta-4 appear on the 2026 WADA Prohibited List.

Frequently Asked Questions

Is BPC-157 proven to heal tendons?

No. Animal tendon research is encouraging, but controlled human evidence establishing tendon-healing effectiveness is lacking.

Is TB-500 the same as thymosin beta-4?

No. They are related, but they should not be treated as interchangeable. TB-500 is a peptide fragment corresponding to a region of thymosin beta-4.

What is the Wolverine Stack?

It is a commonly used community name for combining BPC-157 and TB-500. Popularity of the combination does not establish that the combination improves recovery.

Which peptide is best for recovery?

Current human evidence is not strong enough to establish BPC-157, TB-500 or their combination as a "best" recovery peptide.

Sources

Explore the Handbook

Continue to the BPC-157 profile, TB-500 profile, Research Finder, Goals, Saved Library, or the compound browse and compare view.